These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 6647134)
21. Development of mortality from malignant melanoma in Slovakia compared with Bohemia and some selected countries. Somogyi J; Hostýnová E Neoplasma; 1971; 18(6):649-56. PubMed ID: 5160905 [No Abstract] [Full Text] [Related]
22. Influence of biopsy on the prognosis of cutaneous melanoma of the head and neck. Austin JR; Byers RM; Brown WD; Wolf P Head Neck; 1996; 18(2):107-17. PubMed ID: 8647675 [TBL] [Abstract][Full Text] [Related]
23. [Analysis of the mortality and incidence of cutaneous melanoma in Italy]. Maggini M; Petrelli G; Portoghesi F; Vollono C Ann Ist Super Sanita; 1982; 18(3):591-4. PubMed ID: 7187848 [No Abstract] [Full Text] [Related]
28. Turning the tables on tumors. Mettner J Minn Med; 2004 May; 87(5):18-22. PubMed ID: 15191063 [No Abstract] [Full Text] [Related]
29. Time trends of incidence, mortality, and relative survival of invasive skin melanoma in Lithuania. Stang A; Valiukeviciene S; Aleknaviciene B; Kurtinaitis J Eur J Cancer; 2006 Mar; 42(5):660-7. PubMed ID: 16510281 [TBL] [Abstract][Full Text] [Related]
30. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094 [TBL] [Abstract][Full Text] [Related]
32. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Garbe C; Eigentler TK Melanoma Res; 2007 Apr; 17(2):117-27. PubMed ID: 17496787 [TBL] [Abstract][Full Text] [Related]
33. Malignant melanoma. A REVIEW OF ') YEARS' experience in Glasgow, Scotland. Cochran AJ Cancer; 1969 May; 23(5):1190-9. PubMed ID: 5778237 [No Abstract] [Full Text] [Related]
34. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436 [TBL] [Abstract][Full Text] [Related]
35. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Lasithiotakis K; Leiter U; Meier F; Eigentler T; Metzler G; Moehrle M; Breuninger H; Garbe C Cancer; 2008 Apr; 112(8):1795-804. PubMed ID: 18306371 [TBL] [Abstract][Full Text] [Related]
36. [Study of the sentinel lymph node. Diagnosis and treatment of cutaneous malignant melanoma stages I and II]. Denninghoff V; Falco J; Curutchet HP; Elsner B Medicina (B Aires); 2006; 66(2):144-6. PubMed ID: 16715764 [TBL] [Abstract][Full Text] [Related]
37. [Comment on the contribution by U. Beiteke et al. Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Second comment]. Gefeller O; Kleeberg U; Kölmel KF Hautarzt; 1994 Mar; 45(3):191-2; author reply 193-4. PubMed ID: 8175352 [No Abstract] [Full Text] [Related]